Globes |
Teva's well-traveled asthma drug comes through in Phase III
FierceBiotech The drug, which works by blocking the interleukin-5 pathway, met its primary endpoints in two Phase III studies on patients with inadequately controlled asthma and elevated levels of inflammatory white blood cells, Teva said. In 12-month data from more … Teva finds positive results in advanced trials for asthma drug Teva's Reslizumab Shows Reduction In Asthma Exacerbations In Clinical Studies Teva stakes its claim to the asthma antibody market |
View full post on asthma – Google News